Cantor Fitzgerald Reiterates “Neutral” Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “neutral” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued on Monday, Marketbeat.com reports.

Several other equities analysts also recently weighed in on the stock. The Goldman Sachs Group downgraded shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. HC Wainwright cut their price objective on shares of Gossamer Bio from $10.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 6th. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Finally, Leerink Partners lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.43.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.34 on Monday. The business has a fifty day moving average price of $1.56 and a 200 day moving average price of $2.41. The company has a market cap of $80.95 million, a P/E ratio of -0.46 and a beta of 2.08. Gossamer Bio has a one year low of $0.32 and a one year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 351.49%.The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. As a group, sell-side analysts predict that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors have recently made changes to their positions in GOSS. MMA Asset Management LLC purchased a new stake in shares of Gossamer Bio in the 4th quarter valued at approximately $31,000. Soltis Investment Advisors LLC acquired a new position in shares of Gossamer Bio in the 4th quarter worth approximately $31,000. Ciovacco Capital Management LLC purchased a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $27,000. Beacon Pointe Advisors LLC purchased a new position in shares of Gossamer Bio during the 4th quarter worth approximately $34,000. Finally, Ieq Capital LLC acquired a new stake in Gossamer Bio in the 4th quarter valued at approximately $35,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Neutral Sentiment: Market data shows multiple reports of a large “increase” in short interest for March, but the published figures are inconsistent or zero (short interest = 0 shares; days‑to‑cover = 0.0), suggesting a data anomaly rather than clear new shorting pressure. (May indicate noise rather than a firm fundamental change.)
• Neutral Sentiment: Cantor Fitzgerald’s coverage actions are mixed in feeds: one item notes a downgrade action while another notes a reaffirmed “neutral” rating — the net effect is limited additional negative guidance but confirms tepid analyst sentiment. Cantor Fitzgerald downgrades Gossamer Bio (GOSS)
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Gossamer, signaling potential shareholder litigation tied to recent developments and increasing legal overhang. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
• Negative Sentiment: Levi & Korsinsky announced a shareholders’ alert and investigation into Gossamer, reinforcing regulatory/litigation concerns and adding to investor uncertainty around the company’s pivotal seralutinib program and the PROSERA Phase 3 outcome. Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS)
• Negative Sentiment: Press coverage highlights a clinical setback and declining investor confidence around Gossamer’s lead program (seralutinib/PROSERA), which directly pressures valuation for a clinical‑stage biotech reliant on a single pivotal asset. Investor Confidence Wanes Following Gossamer Bio’s Clinical Setback

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.